Vikram Narayan, MD, Discusses Nadofaragene, Anti-Adenovirus Antibodies and Cystectomy for Patients with NMIBC

Video

Narayan expanded on the other studies he contributed to from SUO investigating nadofaragene for patients with NMIBC.

Vikram Narayan, MD, spoke with CancerNetwork to expand on research published at the 21st Annual Meeting of the Society of Urologic Oncology to treat patients with non-muscle invasive bladder cancer (NMIBC).

Transcription:

One of the other projects we looked at was to measure anti-adenovirus antibodies in patients before each of the treatment doses. So, again, this is an adenovirus-based therapy. We measured anti-adenovirus antibodies in the patients, and we looked to see if that correlated to treatment response. What we found was that significantly more patients who had a 2-fold greater than baseline level of adenovirus antibodies had achieved a complete response compared to non-responders. This may have implications in terms of being able to predict who treatment responders might be and we’re investigating that further.

The last poster that we looked at looked specifically at the question of cystectomy. So, as you know, this is meant to be a bladder sparing treatment option. One question is, well does it prevent or prolong the time to cystectomy, if at all? What our analysis showed was that, among those who eventually underwent cystectomy, patients who had achieved a complete response having received nadofaragene managed to hold off significantly longer than patients who had not achieved a complete response in terms of time to cystectomy. That was found in both groups. There were 2 groups in the study, a CIS group and a non-CIS group, and both groups that was identified in.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Related Content